INmune Bio, Inc.
INmune Bio, Inc. (INMB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · INMB · as of Jun 9, 2026
Key Statistics
Explore INmune Bio, Inc. Data
inmb stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 66.7%
The INMB analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $22.00, representing +1674.19% upside from the current price of $1.24.
Competitors & Peers
inmb competitorsINMB
ALGS
BRNS
CVM
FGEN
MRSNStock Performance
Full HistoryAbout INmune Bio, Inc.
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses.…
what is inmune bio, inc. · inmb stock overview · inmune bio, inc. company profile · who is inmune bio, inc. ceo · inmb NASDAQ · inmune bio, inc. headquarters · inmune bio, inc. business segments
About Stock Overview & Key Data
INmune Bio, Inc. (INMB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 4, 2019. As of the latest trading session, INMB stock price is $1.24, with a market capitalization of $33.0M. The stock has returned -83.79% over the past 12 months and -20.51% year-to-date.
According to 9 Wall Street analysts, the consensus rating for INmune Bio, Inc. stock is Buy, with an average 12-month price target of $22.00. In fiscal year 2025, INmune Bio, Inc. reported revenue of $50000.00 and net income of -$45.9M. For detailed data — including INmune Bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, INmune Bio, Inc. (INMB) stock price is $1.24. The stock is traded on NASDAQ under the ticker symbol INMB. The 52-week range is $1.09 – $11.64.